Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 114 citing articles:

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Pengfei Wang, Manoj S. Nair, Lihong Liu, et al.
Nature (2021) Vol. 593, Iss. 7857, pp. 130-135
Open Access | Times Cited: 2239
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Rita E. Chen, Xianwen Zhang, James Brett Case, et al.
Nature Medicine (2021) Vol. 27, Iss. 4, pp. 717-726
Open Access | Times Cited: 970
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Laura A. VanBlargan, John M. Errico, Peter Halfmann, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 490-495
Open Access | Times Cited: 708
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley, et al.
The Lancet (2021) Vol. 397, Iss. 10282, pp. 1351-1362
Open Access | Times Cited: 624
SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients
Daryl Geers, Marc C. Shamier, Susanne Bogers, et al.
Science Immunology (2021) Vol. 6, Iss. 59
Open Access | Times Cited: 520
Novel SARS-CoV-2 variants: the pandemics within the pandemic
Erik Boehm, Ilona Kronig, Richard A. Neher, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 8, pp. 1109-1117
Open Access | Times Cited: 358
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
Pengfei Wang, Manoj S. Nair, Lihong Liu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 320
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
Pengfei Wang, Manoj S. Nair, Lihong Liu, et al.
(2021)
Open Access | Times Cited: 253
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Emily H. Pilkington, Estelle J. A. Suys, Natalie L. Trevaskis, et al.
Acta Biomaterialia (2021) Vol. 131, pp. 16-40
Open Access | Times Cited: 196
A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
Alexandra Tauzin, Manon Nayrac, Mehdi Benlarbi, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 7, pp. 1137-1150.e6
Open Access | Times Cited: 188
Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection
Federico Gobbi, Dora Buonfrate, Lucía Moro, et al.
Viruses (2021) Vol. 13, Iss. 3, pp. 422-422
Open Access | Times Cited: 186
Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
Daniele Focosi, Fabrizio Maggi
Reviews in Medical Virology (2021) Vol. 31, Iss. 6
Open Access | Times Cited: 161
Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy
Sindhu Ramesh, Manoj Govindarajulu, Rachel S. Parise, et al.
Vaccines (2021) Vol. 9, Iss. 10, pp. 1195-1195
Open Access | Times Cited: 131
Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
Angel Yun-Kuan Thye, Jodi Woan‐Fei Law, Priyia Pusparajah, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1303-1303
Open Access | Times Cited: 120
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
Ahmed O. Hassan, Swathi Shrihari, Matthew J. Gorman, et al.
Cell Reports (2021) Vol. 36, Iss. 4, pp. 109452-109452
Open Access | Times Cited: 119
Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants
Takuya Tada, Hao Zhou, Marie I. Samanovic, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 105
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Baoling Ying, Bradley Whitener, Laura A. VanBlargan, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 630
Open Access | Times Cited: 69
Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies
Takuya Tada, Belinda M. Dcosta, Hao Zhou, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 75
An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status
Sheila Lumley, Gillian Rodger, Bede Constantinides, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 7, pp. 1208-1219
Open Access | Times Cited: 74
Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies
Maryam Noori, Seyed Aria Nejadghaderi, Shahnam Arshi, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 2
Open Access | Times Cited: 73
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Laura A. VanBlargan, John M. Errico, Peter Halfmann, et al.
Research Square (Research Square) (2021)
Open Access | Times Cited: 65
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, et al.
Nature Immunology (2021) Vol. 22, Iss. 10, pp. 1306-1315
Open Access | Times Cited: 63
The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies
Takuya Tada, Hao Zhou, Belinda M. Dcosta, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 62
Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines
Yury Valdés-Balbín, Darielys Santana-Mederos, Françoise Paquet, et al.
ACS Central Science (2021) Vol. 7, Iss. 5, pp. 757-767
Open Access | Times Cited: 61
Page 1 - Next Page

Scroll to top